Galectin Therapeutics
GALT
59 hedge funds and large institutions have $18.2M invested in Galectin Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 11 closing their positions.
863% more call options, than puts
Call options by funds: $154K | Put options by funds: $16K
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
48% more capital invested
Capital invested by funds: $12.3M → $18.2M (+$5.92M)
0.34% more ownership
Funds ownership: 11.98% → 12.32% (+0.34%)
11% less funds holding
Funds holding: 66 → 59 (-7)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$531K |
| 2 |
WANY
Wealthspire Advisors (New York)
New York
|
+$406K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.8K |
| 4 |
Squarepoint
New York
|
+$90.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$351K |
| 2 |
6CM
683 Capital Management
New York
|
-$184K |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
-$90K |
| 4 |
AWS
Atria Wealth Solutions
New York
|
-$66.2K |
| 5 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
-$59.9K |
GALT Hedge Fund Activity: Q1 2024 in Review
59 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2024, worth a combined $18.2M — up 48% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GALT and 4 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Susquehanna International Group, adding an estimated $531K. The largest seller was Morgan Stanley, cutting an estimated $351K.
- 59 institutional investors held Galectin Therapeutics (GALT) as of Q1 2024, down from 66 in Q4 2023.
- Funds reported $18.2M of Galectin Therapeutics stock for Q1 2024, up 48% quarter-over-quarter.
- 4 funds opened new Galectin Therapeutics positions in Q1 2024 and 11 closed out, a net change of -7 holders.
- The largest Galectin Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $531K added.
- The largest Galectin Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $351K sold.
Based on aggregated 13F filings for Q1 2024.